Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d

NCT ID: NCT01787396

Last Updated: 2015-04-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 433 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-04-30
• Study Completion Date: 2015-03-31

Brief Summary

The objective of this study is to evaluate efficacy and safety of initial combination therapy with Gemigliptin 50mg q.d and Metformin q.d compared with either monotherapy in treatment naïve patients with type 2 diabetes, In other words, to proof superiority of initial combination therapy with Gemigliptin and Metformin than each monotherapy.

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Arm1

Gemigliptin 50mg + Metformin Once daily with dinner

Group Type: EXPERIMENTAL

Gemigliptin 50mg

Intervention Type: DRUG

Metformin

Intervention Type: DRUG

Arm 2

Gemigliptin 50mg + Placebo(Metformin)Once daily with dinner

Group Type: EXPERIMENTAL

Gemigliptin 50mg

Intervention Type: DRUG

Placebo(Metformin)

Intervention Type: DRUG

Arm3

Metformin+ Placebo(Gemigliptin 50mg)Once daily with dinner

Group Type: EXPERIMENTAL

Metformin

Intervention Type: DRUG

Placebo(Gemigliptin)

Intervention Type: DRUG

Interventions

Gemigliptin 50mg

Intervention Type: DRUG

Placebo(Metformin)

Intervention Type: DRUG

Metformin

Intervention Type: DRUG

Placebo(Gemigliptin)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with type 2 diabetes mellitus

2. Adults over 20 of age

3. Patients with hemoglobin A1c (HbA1c) over 7.5% at Visit1(screening) and no previous antidiabetic drugs before Visit 1(screening) or patients with hemoglobin A1c (HbA1c) between 7%~10.5%, Patients treated with metformin monotherapy before Visit 1(screening).

Patients with no previous antidiabetic drugs

4. Patients with hemoglobin A1c (HbA1c) between 7.5%~11% at Visit 2(randomization)

Exclusion Criteria

1. Patients with type 1 diabetes mellitus Diabetic ketoacidosis or Hyperosmolar non-ketotic coma.

2. Patients with gestational diabetes, or secondary diabetes

3. Patients with New York Heart Association (NYHA) class III-IV congestive heart failure or patients with arrhythmia requiring treatment

4. Patients with dysfunctional thyroid gland (with abnormal level of TSH)

5. Patients with active bladder cancer.

6. Tests which need to be given radiation iodide dye by intravenous.(ex, intravenous urography, intravenous cholangiography, angiography, CT with dye)

7. Severe infection, pre or post operation.(Simple surgery which does not have restriction of food and fluid), severe trauma patient.

8. Patients with pituitary insufficiency or adrenal dysfunction.

9. Patients with pulmonary infarction, severe pulmonary dysfunction, hypoxemia.

10. Patients with gastrointestinal disorders(ex. Dehydration, Diarrhea, Vomiting)

11. Female patients who is gravida or in lactiferous phase or confirmed pregnancy by serum or urine.

12. Patients with body mass index (BMI) below 20 kg/m2 or exceeding 40 kg/m2

13. Male patients with Serum Creatinine level over 1.5mg/dl, Female patients with serum creatinine over 1.4mg/dl.

14. Patients with alanine aminotransferase (ALT), aspartate aminotransferase (AST), exceeding 2.5 times or bilirubin exceeding 1.5 times of the upper limit of the normal range

15. Patients who were taking or needed to take any drugs that may affect the control of blood glucose significantly (ex. glucocorticoids)

16. Patients taking thyroid hormone, warfarin, dicoumarin or digoxin.

17. Patients taking CYP3A4 inducers.(ex, Rifampicin(Rifampin), Dexametha-sone, Phenytoin, Carbamazepine, Rifabutin, Phenobarbital)

18. Patients taking Furocemide, Nifedipine, Cimetidine

19. Patients who were treated with Anti-obesity drugs in the last 12 weeks prior to Visit 1(screening)

20. Patients who were treated with insulin or glucagon-like peptide-1 (GLP-1) analogue or in the last 6 months prior to Visit 1.

21. Patients who had experienced myocardial infarction, unstable angina or prior history of coronary artery bypass surgery within 6 months prior to Visit1(screening), or patients with arrhythmia requiring treatment

22. Patients with history of addiction to alcohol or drugs within 1year prior to Visit 1(screening).

23. Patients with history of Diabetic ketoacidosis or Hyperosmolar non-ketotic coma.

24. Patients with history of hypersensitivity to gemiglpitin or Dipeptidyl-peptidase4(DPP4) inhibitors.

25. Patients with history of hypersensitivity to metformin or biguanides.

26. Patients with history of hypersensitivity to Pioglitazone HCl or Thiazolidinediones

27. Patients who participated in other clinical trial within 3 months prior to Visit1(screening).

28. Patients with other reasons who the investigator decided not to be eligible for the study

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LG Life Sciences

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

LG Life Sciences

Seoul, , South Korea

Countries

South Korea

Other Identifiers

LG-DPCL011

Identifier Type: -

Identifier Source: org_study_id